Jump to content

James L. Gulley

Add links
From Wikipedia, the free encyclopedia
This article is about the cancer researcher. For the basketball player, see James Gulley (basketball).
James L. Gulley
EducationLoma Linda University, Emory University, National Cancer Institute
Medical career
ProfessionMedical oncologist
InstitutionsNational Cancer Institute
Sub-specialtiesgenitourinary oncology, immunotherapy
Researchcancer research
Website

James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.[1]

Early life and education

[edit]

He graduated from Loma Linda University, California[2] and his M.D./Ph.D. Medical Scientist Training Program, at National Institutes of Health (NIH) and his dissertation on tumor immunology.[3] Later, Gulley did his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI.[4]

Research and career

[edit]

Gulley did his research in immunotherapy for prostate cancer. His studies involved the use of cancer vaccine[5] and immune checkpoint inhibitors or other strategies to enhance vaccine-mediated killing.[6] Since 1999, he ran clinical trials at the NCI,[7] serving as Principal Investigator or an Associate Investigator on approximately 40 trials. He is also running studies on cancer patients.[8][9][10]

Publications

[edit]

He published over 250 research papers & book chapters across leading journals.[11][12] Some of his notable publications are listed below:

  • Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer[13]
  • Androgen deprivation therapy for prostate cancer[14]
  • Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer[15]
  • Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer[16]
  • Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM[17]
  • A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.[18]
  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer[19]
  • Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial[20]

FDA approval

[edit]

At the 2010 ASCO meeting Gulley and his group reported on the use of Ipilimumab with a vector-based vaccine for treating advanced prostate cancer. This phase I trial using PSA-TRICOM with Ipilimumab (Ipi) showed promise for Overall Survival (OS).[21] Ipi is used in melanoma vaccine clinical trials.[22] It was approved by the FDA in March 2011.[23][24][25][26]

Awards

[edit]
  • He received Presidential Early Career Award for Science and Engineering “For randomized, controlled studies using novel, recombinant vaccines to reduce the progression of prostate and other cancers and increase survival.” [27][28]
  • He received Federal Laboratory Consortium Excellence in Federal Technology Transfer Award, a national award for “Development of first immunotherapy to treat chordoma, a rare bone cancer.”[29]

References

[edit]
  1. ^ "Medical Oncology Service". Center for Cancer Research. 2016-02-09. Retrieved 2019-08-22.
  2. ^ "James L. Gulley, M.D., Ph.D." Center for Cancer Research. 2014-08-12. Retrieved 2019-11-16.
  3. ^ "Principal Investigators". NIH Intramural Research Program. Retrieved 2019-08-06.
  4. ^ "Medical Oncology Web - FELLOWSHIP". Medicaloncology.cancer.gov. Retrieved 2010-07-14.
  5. ^ Gulley, James L.; Arlen, Philip M.; Schlom, Jeffrey (2007-07-01). "Cancer Vaccines: Moving Beyond Current Paradigms". Clinical Cancer Research. 13 (13): 3776–3782. doi:10.1158/1078-0432.CCR-07-0588. ISSN 1078-0432. PMC 2536755. PMID 17606707.
  6. ^ "James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options - The ASCO Post". ascopost.com. Retrieved 2019-08-22.
  7. ^ Gulley, James (2015-02-23). "James Gulley". NIH Intramural Research Program. Retrieved 2019-11-16.
  8. ^ "Clinical Trials at NIH: Health Care Professionals: Investigator Profiles: James L. Gulley, M.D". Bethesdatrials.cancer.gov. Archived from the original on 2010-05-27. Retrieved 2010-07-14.
  9. ^ "Clinical Trials at NIH: Health Care Professionals: Investigator Profiles: James L. Gulley, M.D." 2010-05-27. Archived from the original on 2010-05-27. Retrieved 2019-08-22.
  10. ^ "Genitourinary Malignancies Branch Clinical Trials". Center for Cancer Research. Retrieved 2019-08-22.
  11. ^ "My Bibliography James Gulley's Bibliography".
  12. ^ "Center for Cancer Research - Staff Pages". Ccr.cancer.gov. Archived from the original on 2010-05-27. Retrieved 2010-07-14.
  13. ^ Kantoff, Philip W.; Schuetz, Thomas J.; Blumenstein, Brent A.; Glode, L. Michael; Bilhartz, David L.; Wyand, Michael; Manson, Kelledy; Panicali, Dennis L.; Laus, Reiner (2010-03-01). "Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer". Journal of Clinical Oncology. 28 (7): 1099–1105. doi:10.1200/JCO.2009.25.0597. ISSN 1527-7755. PMC 2834462. PMID 20100959.
  14. ^ Dahut, William L.; Gulley, James L.; Sharifi, Nima (2005-07-13). "Androgen Deprivation Therapy for Prostate Cancer". JAMA. 294 (2): 238–244. doi:10.1001/jama.294.2.238. ISSN 0098-7484. PMID 16014598.
  15. ^ Dahut, William L.; Gulley, James L.; Arlen, Philip M.; Liu, Yinong; Fedenko, Katherine M.; Steinberg, Seth M.; Wright, John J.; Parnes, Howard; Chen, Clara C. (2004-07-01). "Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer". Journal of Clinical Oncology. 22 (13): 2532–2539. doi:10.1200/JCO.2004.05.074. ISSN 0732-183X. PMID 15226321.
  16. ^ Gulley, James L.; Arlen, Philip M.; Bastian, Anne; Morin, Steven; Marte, Jennifer; Beetham, Patricia; Tsang, Kwong-Yok; Yokokawa, Junko; Hodge, James W. (2005-05-01). "Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer". Clinical Cancer Research. 11 (9): 3353–3362. doi:10.1158/1078-0432.CCR-04-2062. ISSN 1078-0432. PMID 15867235.
  17. ^ Marshall, John L.; Gulley, James L.; Arlen, Philip M.; Beetham, Patricia K.; Tsang, Kwong-Yok; Slack, Rebecca; Hodge, James W.; Doren, Sandra; Grosenbach, Douglas W. (2005-02-01). "Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas". Journal of Clinical Oncology. 23 (4): 720–731. doi:10.1200/JCO.2005.10.206. ISSN 0732-183X. PMID 15613691.
  18. ^ Arlen, Philip M.; Gulley, James L.; Parker, Catherine; Skarupa, Lisa; Pazdur, Mary; Panicali, Dennis; Beetham, Patricia; Tsang, Kwong Y.; Grosenbach, Douglas W. (2006-02-15). "A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer". Clinical Cancer Research. 12 (4): 1260–1269. doi:10.1158/1078-0432.CCR-05-2059. ISSN 1078-0432. PMC 1526707. PMID 16489082.
  19. ^ Gulley, James L.; Arlen, Philip M.; Madan, Ravi A.; Tsang, Kwong-Yok; Pazdur, Mary P.; Skarupa, Lisa; Jones, Jacquin L.; Poole, Diane J.; Higgins, Jack P. (2010). "Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer". Cancer Immunology, Immunotherapy. 59 (5): 663–674. doi:10.1007/s00262-009-0782-8. ISSN 1432-0851. PMC 2832083. PMID 19890632.
  20. ^ Madan, Ravi A.; Mohebtash, Mahsa; Arlen, Philip M.; Vergati, Matteo; Rauckhorst, Myrna; Steinberg, Seth M.; Tsang, Kwong Y.; Poole, Diane J.; Parnes, Howard L. (2012). "Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial". The Lancet. Oncology. 13 (5): 501–508. doi:10.1016/S1470-2045(12)70006-2. ISSN 1474-5488. PMC 6359905. PMID 22326924.
  21. ^ Madan, Ravi A.; Mohebtash, Mahsa; Arlen, Philip M.; Vergati, Matteo; Rauckhorst, Myrna; Steinberg, Seth M.; Tsang, Kwong Y.; Poole, Diane J.; Parnes, Howard L. (2012). "Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial". The Lancet. Oncology. 13 (5): 501–508. doi:10.1016/S1470-2045(12)70006-2. ISSN 1474-5488. PMC 6359905. PMID 22326924.
  22. ^ Sarnaik, A. A.; Yu, B.; Yu, D.; Morelli, D.; Hall, M.; Bogle, D.; Yan, L.; Targan, S.; et al. (2010). "Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma". Clinical Cancer Research. 17 (4): 896–906. doi:10.1158/1078-0432.CCR-10-2463. PMC 3041838. PMID 21106722.
  23. ^ Hoos, Axel; Ibrahim, Ramy; Korman, Alan; Abdallah, Kald; Berman, David; Shahabi, Vafa; Chin, Kevin; Canetta, Renzo; Humphrey, Rachel (2010). "Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy". Seminars in Oncology. 37 (5): 533–46. doi:10.1053/j.seminoncol.2010.09.015. PMID 21074069.
  24. ^ "Experimental Drug Improves Survival in Advanced Melanoma - National Cancer Institute". www.cancer.gov. Archived from the original on 2010-08-11.
  25. ^ Madan, Ravi A.; Mohebtash, Mahsa; Arlen, Philip M.; Vergati, Matteo; Rauckhorst, Myrna; Steinberg, Seth M.; Tsang, Kwong Y.; Poole, Diane J.; Parnes, Howard L. (2012). "Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial". The Lancet. Oncology. 13 (5): 501–508. doi:10.1016/S1470-2045(12)70006-2. ISSN 1474-5488. PMC 6359905. PMID 22326924.
  26. ^ Schlom, Jeffrey; Gulley, James L. (2018-12-04). "Vaccines as an Integral Component of Cancer Immunotherapy". JAMA. 320 (21): 2195–2196. doi:10.1001/jama.2018.9511. ISSN 1538-3598. PMC 6538063. PMID 30419097.
  27. ^ "President Obama Honors Outstanding Early-Career Scientists". whitehouse.gov. 2011-09-26. Retrieved 2019-08-22.
  28. ^ "CCR Connections (News) - An Early Career Off to a Stellar Start". home.ccr.cancer.gov. Retrieved 2019-08-22.
  29. ^ "Recent CCR Awards". Center for Cancer Research. 2016-06-21. Retrieved 2019-08-22.
[edit]
Retrieved from "https://wiki.riteme.site/w/index.php?title=James_L._Gulley&oldid=1218410571"